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Abstract
Background: The genetic mechanisms underlying hemangioblastoma development are still largely unknown. We
used high-resolution single nucleotide polymorphism microarrays and droplet digital PCR analysis to detect copy
number variations (CNVs) in total of 45 hemangioblastoma tumors.
Results: We identified 94 CNVs with a median of 18 CNVs per sample. The most frequently gained regions were on
chromosomes 1 (p36.32) and 7 (p11.2). These regions contain the EGFR and PRDM16 genes. Recurrent losses were
located at chromosome 12 (q24.13), which includes the gene PTPN11.
Conclusions: Our findings provide the first high-resolution genome-wide view of chromosomal changes in
hemangioblastoma and identify 23 candidate genes: EGFR, PRDM16, PTPN11, HOXD11, HOXD13, FLT3, PTCH, FGFR1,
FOXP1, GPC3, HOXC13, HOXC11, MKL1, CHEK2, IRF4, GPHN, IKZF1, RB1, HOXA9, and micro RNA, such as hsa-mir-196a-2
for hemangioblastoma pathogenesis. Furthermore, our data implicate that cell proliferation and angiogenesis
promoting pathways may be involved in the molecular pathogenesis of hemangioblastoma.
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Background
Hemangioblastomas (HB) are highly vascular tumors,
which account for approximately 3 % of all tumors of the
central nervous system (CNS) [1]. It occurs in a subset of
CNS locations, including the cerebellum (37 %), brainstem
(10 %), and spinal cord (50 %) [1]. They are classed as
grade one tumors under the World Health Organization's
classification system. While most of these tumors are low
grade and benign, some hemangioblastomas can present
aggressive and occasionally malignant behavior. Heman-
gioblastomas occur as sporadic tumors (75 %) or as a
manifestation of an autosomal dominantly inherited
disorder, von Hippel-Lindau (VHL) disease (25 %) [2].
VHL hemangioblastomas are most commonly caused by
germline exon deletions or truncating mutations [3] of the
Von Hippel-Lindau (VHL) tumor-suppressor gene. The
VHL protein, which is the critical part of a ubiquitin ligase
protein complex that binds to the hypoxia-inducing
factors HIF-1 and HIF-2 transcription factors and targets
them for ubiquitination and proteosomal degradation.
Dysregulation of this VHL-associated function causes in-
creased expression of a variety of growth factors, including
erythropoietin, PDGF, VEGF and TGF. Upregulation of
these factors may lead to angiogenesis and tumorigenesis.
Additional mechanisms of tumorigenesis have been de-
scribed outside of the HIF pathway, including alterations
in microtubule binding and stabilization, abnormal
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extracellular matrix composition as well as apoptosis and
transcription regulation [4]. For most VHL disease related
hemangioblastomas, the inactivation or loss of both alleles
of the VHL gene is required. In addition to the phenotypic
variability associated with allelic heterogeneity, genetic
modifiers may influence the phenotypic expression of
VHL disease. Allelic variants in the CCND1, MMP1 and
MMP3 genes have been reported to influence hemangio-
blastoma development [5]. This reiterates the need for
elucidating other genetic alterations specific for heman-
gioblastoma beside the hits of VHL gene. Moreover, in a
subset of tumors including mostly sporadic hemangioblas-
tomas, the genetic pathways involved in tumorigenesis
have not been defined yet [6].
Copy number variants (CNVs) are alterations of
DNA sections in result of genomic deletions (fewer
than the normal number) or duplications (more than
the normal number) on certain chromosomes and
are common to many human cancers. Comparative
genomic hybridization (CGH) by single nucleotide
polymorphism (SNP) arrays is a cutting edge tech-
nology that allows characterization of CNVs. SNP
array karyotyping provides genome-wide assessment
of copy number and loss of heterozygosity (LOH) in
one assay. SNP array platforms, such as Affymetrix
SNP 6.0 (Affymetrix, Santa Clara, CA, USA), often
identify amplifications/deletions at a single gene
level, which could not have been accomplished by
previous methods. Thus, modern SNP arrays offer a
powerful method for the discovery of oncogene and
tumor suppressor gene involvement in tumors, as
well as for improved cancer classification [7].
In contrast to surveillance of genome wide alterations
by CGH arrays it is possible to directly quantify the abso-
lute copy number of specific DNA loci by Droplet Digital
PCR (ddPCR). In ddPCR, target sequences are amplified
by PCR and the reaction products are partitioned into
droplets and amplified to endpoint with TaqMan probes
as in qPCR, then their concentrations are determined
based on the number of fluorescently positive and nega-
tive droplets in a sample well. The absolute number of
target and reference DNA molecules is calculated and
provides the target copy number variation (CNV) [8].
In the present study we used high-resolution SNP arrays
for the first time to genome wide analysis of aberrations in
hemangioblastomas aiming at the identification of novel
pathogenetic mechanisms and possible targets for rational
therapy. We validated the main reoccurring genetic
changes by ddPCR highly precise quantification.
Methods
Study population
A total of 44 hemangioblastoma samples were used for
the present study. Thirteen frozen samples obtained
from The Sourasky Medical Center, Tel Aviv, Israel were
used for the CGH analysis. Additional 32 formalin fixed
paraffin embedded (FFPE) samples from Sheba Medical
Center, Tel Hashomer, Israel were used as validation
group. The study was approved by the ethical review
boards of both Sheba and Tel Aviv Sourasky Medical
Centers and was consistent with the declaration of
Helsinki including informed consents. Clinical parame-
ters, such as sex, age at diagnosis, and pathologic classi-
fication were collected from patient records. Clinical
information of the patient’s cohort is outlined in Table 1.
CGH analysis
DNA was purified from frozen tissues using DNeasy
(Qiagen Inc., Valencia, CA). One sample of pooled nor-
mal genomic DNA, provided by Affymetrix, was used as
experimental positive control. 250 ng of genomic DNA
was digested with NspI (New England Biolabs, Inc) and
then ligated to Nsp adaptors. The adaptor-ligated DNA
fragments were amplified, fragmented using DNase I,
end labelled with a biotinylated nucleotide, and hybrid-
ized to a human cytoscan HD array (Affymetrix) at 50 °
C for 17 h. After hybridization, the arrays were washed,
stained, and finally scanned with a GeneChip scanner
3000 (Affymetrix). All procedures were performed ac-
cording to the manufacturer’s protocols. Array experi-
ments were performed using the high-resolution
Affymetrix CytoScan HD microarray (Affymetrix, Inc,
Santa Clara, CA) containing 2,696,550 markers of which
1,953,246 are non-polymorphic markers and 750,000
SNPs with over 99 % accuracy to detect accurate break-
point estimation as well as loss of heterozygosity (LOH) de-
termination. This chip covers 340 International Standards
for Cytogenomic Arrays (ISCA) constitutional genes, 526
cancer genes (99.6 %) and 36,121 RefSeq genes. The chip
uses marker intervals of 25 markers / 100 kb. Analysis of
CEL files from the Affymetrix CytoScan HD Array or
Cytogenetics Whole-Genome 2.7 M Array was done
with the Chromosome Analysis Suite (ChAS) software
for cytogenetic analysis. Signal processing was done by
Signal Covariate Adjustment, Fragment Correction,
Dual Quantile Normalization and PLIER signal
summarization. Dual Quantile Normalization was
done to equalize each array’s intensity distribution
copy number and SNP probes separately. For SNP
Table 1 Cohort characteristics
Characteristic Frozen Paraffin
Average age 48.5 53.5
Median age 51 53
Spinal samples 4 3
Brain samples 8 29
Total number 12 32
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markers, multiple probes for each allele were summa-
rized to single values. Copy number (CN) was calcu-
lated by hidden Markov model copy number segments
after log2 calculation, high pass filter image correc-
tion, log2 ratio covariate adjustment and systematic
residual variables removal. The baseline for CN = 2
(normal autosomal copy number state) was established
and used by the analysis software by Affymetrix com-
pany using a set of 380 phenotypically normal individ-
uals named as reference. The reference sample
includes 186 females and 194 male. For chromosome
X, only females were used and for chromosome Y only
males were used. Log2 ratios for each marker are
calculated relative to the reference signal profile. Re-
sults of the summarized Data (CYCHP files) were
viewed as chromosomal aberrations in table and
graphical formats. We also added visual inspection of
probe performance for altered segments. Reference in-
tensity intended to represent the copy normal state
(typically 2). Log ratios above 0 mean CN gain, log ra-
tios below 0 mean CN loss and log ratios around 0
represent no change. Abnormal DNA copy numbers
are identified automatically using 25 markers for loss/
50 markers for gains.
VHL sequencing
To screen the VHL gene for mutations in our cohort, we
performed direct sequencing of the coding region. Exons
1, 2 and 3 of the VHL gene and their immediately flank-
ing sequences were amplified by PCR as described previ-
ously [9]. The PCR amplification products were purified
by using the QIAquick PCR Purification Kit (Qiagen),
according to the manufacturer’s instructions. The ampli-
fication primers were used as primers in the sequencing
reactions, except for exon 1, for which we designed a
new cycle sequencing primer (5′CGAAGATACGGAGG
TCGA3′). Cycle sequencing was performed using the
ABI PRISM Big Dye Terminator Cycle Sequencing
Ready reaction kit (Applied Biosystems, Foster City, CA,
USA), followed by isopropanol precipitation. The frag-
ments were sequenced by automated sequencing analysis
on an ABI Prism 377 sequencer (Applied Biosystems).
Droplet digital PCR
Copy Number validation was done on all samples, fro-
zen and paraffin embedded, hemangioblastoma biop-
sies. Genomic DNA was purified using QIAamp DNA
mini (Qiagen). Copy number variation (CNV) test was
performed by droplet digital PCR (ddPCR) as previ-
ously described [10]. In short, 16 ng of genomic DNA
samples were added to 2xddPCR supermix (Bio-Rad)
with final concentration of 500nM of each primer and
250nM probe in duplex of the tested gene and RNaseP.
RNaseP served as a CNV = 2 reference gene. Probes for
the tested genes contained a FAM reporter and RNaseP
contained HEX. The genomic DNA and PCR reaction
mixtures were partitioned into an emulsion of approxi-
mately 20,000 droplets using the QX100 droplet gener-
ator (Bio-Rad, USA). The droplets were transferred to a
96-well PCR plate, heat sealed, and placed in a conven-
tional thermal cycler. Thermal cycling conditions were:
95oC for 10 min followed by 40 cycles of 94oC for 30 s,
60oC for 60 s and one cycle of 98oC for 10 min and
finally 4oC hold. Following PCR, the plates were loaded
into QX100 droplet reader (Bio-Rad) and the CNV value
was calculated using Quantasoft software (Bio-Rad, USA).
Primers and probes for selected areas enlisted in Table 2
were designed using Primer Express software (PE Corp,
USA) and specificity was verified using NCBI BLAST on-
line tool (National Library of Medicine, USA). RNaseP
primers and probes were obtained from Bio-Rad.
Results
SNP array profiling identifies recurrent CNVs
The systematic genome-wide gain and loss segments
based CNVs data detected by SNP profiling in hema-
gioblastoma is detailed in the karyoview (Fig. 1). We
identified 94 CNVs with a median of 18 CNVs per
sample. Twenty-three of them involved noncoding
regions in centromeres that are known to harbor
spurious CNVs, most of them were less than 100 Kb
long, and 56 were found in at least two samples. The
most frequently gained regions were on chromosomes
1 (p36.32) and 7 (p11.2). These regions contain the
PRDM16 and EGFR genes, respectively. Recurrent
losses were located at chromosome 12 (q24.13) which
includes the PTPN11 gene. Pathway analysis revealed
that EGFR, Notch and HedgeHog signaling were the
most frequently altered pathways promoting angiogen-
esis and proliferation. Mir 551a (part of PRDM16)
gain was detected in seven samples, miR-196a-2 gain
was observed in five samples and miR-196b gain was
detected in four samples. The list of recurrent CNVs
found in at least five specimens (Fisher exact test p-value <
0.05), including type of alteration, involved chromosome,
cytobands, and overlapping genes/miRNAs according to
the RefSeq database is provided in Table 3. Two samples
had LOH affecting the CHECK2 region (Fig. 2).
VHL status
We determined the VHL mutation status of our discov-
ery cohort by both DNA sequencing and results from
the CGH arrays. In two of the thirteen frozen samples
(samples 7 and 10) VHL deletions were detected by our
CGH analyses. The deletion in sample 7 encompassed
332 kb with 564 markers. The deletion in sample 10
was shorter (135 kb) with 344 markers. Figure 3 illus-
trates the smooth signal obtained in chromosome band
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3p25.3 for these samples. Sequencing based mutational
analysis of VHL did not reveal any additional muta-
tions. Samples 7 and 10 incurred CNVs similarly to the
other samples. The average number of CMVs in the
other samples was seven. Sample 7 had 14 of the com-
mon CNVs thus had more than the average CNVs but
sample 10 had less CNVs (six) which is similar to the
average.
CNV validation by digital droplet PCR
We validated our findings in a subset of four genes
(EGFR, CHECK2, PTCH1 and PTPN11) in the discovery
cohort used for the array CGH and in an additional
independent set of 32 FFPE specimens, using copy vari-
ation detection by digital droplet PCR (ddPCR) analysis.
Samples were partitioned into thousands of nanoliter-
sized droplets; single template molecules were amplified
Table 2 Digital PCR primers and probes for selected areas
Gene Oligonucleotides Sequence (5′-3′) reporter
PTPN11 Forward primer TTAGAGACAGGGTCCCACTCTTG -
Reverse primer GCTTGAGGATGCAGTAAGCTATGA -
Probe CCTGGCTGGAGTGCAGTGGCGT FAM
CHECK2 Forward primer CATTTTTCTCTTAGTATCTTTCTGGGAAT -
Reverse primer CATTTCTGAGCCCAGCAATACA -
Probe TCACAATCCAGGGCTACAGTAAGACCCATG FAM
PTCH1 Forward primer GCGTGCGAAGGTGGAGACT -
Reverse primer TCATTGGCCTCCCACTTGA -
Probe TGTCTTCTCCCCCATGTCGG FAM
EGFR Forward primer AGGAGGAACAACGTGGAGACA -
Reverse primer GAGACACCGGAGCCACAGA -
Probe CCCAGAGGTGGAACGTTGGCCC FAM
RNaseP Forward primer GATTTGGACCTGCGAGCG -
Reverse primer GCGGCTGTCTCCACAAGT -
Probe CTGACCTGAAGGCTCT Hex
Fig. 1 Ideogram illustrating genome-wide distribution of DNA amplifications and deletions (copy number variation) on each chromosome. Each
line next to the chromosome represents one sample. Gains in copy number are represented by triangles pointing upwards and losses in copy
number are represented by triangles pointing downwards with indication of gene in that region. Chromosome numbers are indicated in boxes
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on a thermocycler, and counted for fluorescent signal.
Absolute copy numbers of target and reference se-
quences were determined by Poisson algorithms [8]. The
RNase P (Ribonuclease P) amplicon maps within the sin-
gle exon RPPH1 gene on 14q11.2 was used as the stand-
ard reference assay for copy number analysis [11].
Validation results were as follows: EGFR amplification
was detected in 29 of 32 patient samples (Fig. 4),PTCH1was
amplified in 18 of 32 patients (Fig. 5) and CHEK2 was
deleted in 27of 32 (Fig. 6). Surprisingly,PTPN11wasdeleted
in 7/32whilst it was amplified in 17/32 specimens (Fig. 7).
It is important to note that in result of normal cell admix-
ture within tumor samples a high CNV means either high
fraction of tumor cells with relatively high copy number in
each cell or low fraction of tumor cells with very high copy
number in each cell. Likewise, low CNV means either high
fraction of tumor cells with relatively low copy number in
each cell or low fraction of tumor cells with relatively very
Table 3 Frequent chromosome losses and gains involving single genes
Number of samples Type Chromo some Band Gene miRNA GV
7 Gain 7 p11.2 EGFR -
7 Gain 1 p36.32 PRDM16 hsa-mir-551ahsa-mir-551a v
7 Loss 12 q24.13 PTPN11 -
7 Gain 2 q31.1 HOXD11, HOXD13 HOHOHOXD13
HOXD11HOXD13
v
6 Loss 13 q12.2 FLT3 -
6 Gain 9 q22.32 PTCH v
5 Loss 8 p11.22 FGFR1 -
5 Loss 3 p13 FOXP1 -
5 Gain X q26.2 GPC3 -
5 Gain 12 q13.13 HOXC13, HOXC11 hsa-mir-196a-2 v
5 Loss 22 q13.1 MKL1 v
5 Loss 22 q12.1 CHEK2 v
The column “Number of samples” represents the number of patients with a particular genomic abnormality. For each variation the type of variation (gain or loss),
location on chromosome and band, the gene located in this locus and miRNAs located in this locus are enlisted. Variants reported in the Database of Genomic
Variants (DGV) database in genes are denoted as “v” and if none reported as “-” under the column DGV
Fig. 2 CHECK2 copy number state. CHECK2 locus is labeled by centrally located data track with dashed line. The data point scores form a
trinomial distribution about the values 2, 0 and −2, where values around 0 represent heterozygous SNPs, while homozygous SNPs have a value of
approximately 2 or −2. LOH is located on genomic region with a scarcity of heterozygous SNP calls. a Sample 6 and (b) Sample 13 exhibit LOH
of CHECK2 region, (c) The control sample exhibits normal copy number state
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low copy number in each cell. In short if the fraction of
tumor cells is low then the relative copy number (both high
and low CNV) is even higher than what is reported. In our
cohort, histopathologic assessment by a pathologist deter-
mined that 47 percent of samples had more than 95 %
tumor, 7 percent had more than 90 % tumor, 29 percent of
samples had more than 70–80 % tumor, 14 percent of sam-
ples had between 50–70 % tumor and 3 percent had
between 40–50 % tumor.
Discussion
We report here for the first time a genome-wide, high-
resolution systematic analysis of chromosomal changes in
hemangioblastoma. Using the SNP array 6 (Affymetrix)
we analyzed 1.8 million genetic markers genome wide to
identify amplifications/deletions up to single gene level.
We identified a total of 94 CNVs, 23 of them involved
noncoding regions. 56 (31 gains and 25 losses) were found
in at least two specimens. The most frequently gained
regions were on chromosomes 1 (p36.32) and 7 (p11.2).
The most frequently deleted region was on chromosome
12 (q24.13).
Our findings provide the first high-resolution genome-
wide view of chromosomal changes in hemangioblastoma
and identify 23 common, ie found in 4 or more patients,
candidate genes for hemangioblastoma pathogenesis
(Table 3): EGFR, PRDM16, PTPN11, HOXD11, HOXD13,
FLT3, PTCH, FGFR1, FOXP1, GPC3, HOXC13, HOXC11,
MKL1, CHEK2, IRF4, GPHN, IKZF1, RB1, HOXA9,
HOXA11 and several microRNA, including hsa-mir-196a-
2. We note that some of these microalterations have been
reported very rarely previously in tissue samples from
Fig. 3 VHL locus (Ch.3 p25.3) deletion data display. The smooth signal derived from the raw data is displayed. The smooth signal value is
calculated using the intensity values of the flanking probes and the data is displayed by a continuous line which is filled down to the x axis.
Focusing on VHL locus was done by selecting the specific region of the chromosome and zooming in such that this region spans the entire x-
axis. The data points containing the probe values are overlaid on the graph. Smooth signal value can be between zero or four depending on the
Log(2) ratio raw values of the surrounding probes. a Sample 7 and (b) Sample ten smooth signal is one exhibiting deletion in VHL locus (labeled
with dashed line). Probes around the area are normal (around 2)
Fig. 4 EGFR Copy number variation (CNV) values for clinical samples and one normal genomic DNA sample. Genomic DNA copy number
alterations were assessed via ddPCR. The CNV is shown as the number of copies and the Poisson distribution at 95 % confidence interval. The
copy number value of normal diploid sequence has a score of two. Copy number above two means amplification in that region and copy
number below two means deletion in that region
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healthy subjects (according to Database of Genome
Variants (DGV), which are reported in Table 3. However, in
our tumor samples these alterations are significantly more
common (p < 0.00001).
Functional annotation analysis by David [12] reviled that
two pathways are prominently affected in the hemangio-
blastoma samples: the cell proliferation and angiogenesis
promoting pathways. The cell proliferation pathway in-
cludes the following genes: CHEK2, EGFR, FGFR, FLT3
and PTCH1. The angiogenesis pathway includes the genes
EGFR and FGFR, which are significant because they are
also involved in blood vessel formation. Importantly, three
of these genes were verified by ddPCR: EGFR, CHEK2 and
PTCH1. Furthermore, PTPN11 was selected for verification
as it was lost strikingly often (Table 3).
Epidermal growth factor receptor (EGFR) is a tyrosine
kinase receptor that has been documented with increased
expression in a variety of human cancers such as breast
cancer, [13], early stage non-small-cell lung cancers and
gliomas [14, 15]. Our findings are in line with three prior
immunohistochemical studies that found EGFR overexpres-
sion in hemangioblastomas [16] [17] [18]. Fibroblast growth
factor receptor 1 (FGFR1) micro deletions have been
reported in myeloid and lymphoid neoplasms [19]. Interest-
ingly we discovered that the FGFR1 deletion involves the
FGFR1 2nd intron (chromosome 8, 38291333–38314367),
which according to UCSC genome browser hg19 includes a
regulatory site. Checkpoint kinase 2 (CHEK2) has been
implicated in DNA repair, cell cycle arrest, and apoptosis in
response to DNA double-strand breaks [20]. Mutations in
CHEK2 have been reported to be possibly associated with
breast cancer and liposarcoma development [21, 22]. The
protein patched homolog 1 (PTCH1) is a sonic hedgehog
receptor. Loss of function mutations in PTCH1 are associ-
ated with development of various types of cancers, includ-
ing medulloblastoma [23, 24], pancreatic cancer [25] and
Fig. 5 PTCH1 Copy number variation (CNV) values for clinical samples and one normal genomic DNA sample. Genomic DNA copy number
alterations were assessed via ddPCR. The CNV is shown as the number of copies and the Poisson distribution at 95 % confidence interval. The
copy number value of normal diploid sequence has a score of two. Copy number above two means amplification in that region and copy
number below two means deletion in that region
Fig. 6 CHEK2 Copy number variation (CNV) values for clinical samples and one normal genomic DNA sample. Genomic DNA copy number
alterations were assessed via ddPCR. The CNV is shown as the number of copies and the Poisson distribution at 95 % confidence interval. The
copy number value of normal diploid sequence has a score of two. Copy number above two means amplification in that region and copy
number below two means deletion in that region
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colorectal cancer [26]. In contrast to these observations, we
find consistent PTCH1 gains in our cohort of hemangio-
blastoma patients (Table 3). In support of our findings there
are reports of PTCH1 also acting as an oncogene in a
mouse model of skin basal cell carcinomas [27].
FMS-like tyrosine kinase 3 (FLT3) plays a role in
hematopoiesis including early hematologic differentiation
and early B and T-cell development [28] and dendritic
cells differentiation [29]. Activating FLT3 mutations are
some of the most common molecular abnormalities in
acute myeloid leukemia (AML) [30]. Interestingly, in our
data, we find losses of FLT3 (Table 3). Consistent with our
findings, others have reported deletions in FLT3 in AML
as well [31] [32]. Among the altered genes mapped in
many of the recurrently gained regions we recognized
several HOX genes (Table 3) and microRNAs (miRNAs)
residing in the same region. HOX genes encode master
transcription factors important in development and have
been reported to be commonly altered in human solid tu-
mors [33]. On the other hand, miRNAs are small regula-
tory RNAs that have recently been implicated in a variety
of cancers [34]. miR-196a-2 and miR-196b gain were the
most common miRNA CNV in our patients. Interestingly,
miR-196a-2 differs from miR-196b by one nucleotide [35].
The miR-196 gene family is located in the regions of
homeobox (HOX) transcription factors that are essential
for embryogenesis. Up-regulation of miR-196a has been
found in breast cancer, adenocarcinoma, leukemia and
esophageal adenocarcinoma [35]. Accordingly the relevant
causative change may actually be altered miRNA expres-
sion rather than HOX gene expression. Other studies have
reported a 12-fold increase in miR-9 and a 15-fold de-
crease of miR-200a in hemangioblastomas distinguishing
hemangioblastomas from metastatic clear cell renal cell
carcinomas in the CNS [36]. Prdm16 is preferentially
expressed by stem cells throughout the nervous and
haematopoietic systems and promotes stem cell mainten-
ance [37]. Megakaryoblastic leukemia protein-1 (MKL1),
is a transcription factor that regulates many processes,
including remodeling of neuronal networks and epithelial-
mesenchymal transition [38]. Moreover, deregulation by
genetic alterations and/or altered MKL1 transcription has
been shown to have role in myeloproliferative neoplasms
[39]. Finally and most interestingly, protein tyrosine phos-
phatase, non-receptor type 11 (PTPN11) gene encodes the
tyrosine phosphatase SHP2 protein required for RTK
signaling and has a role in survival, proliferation and
differentiation [40]. The fact that we find the PTPN11
gene is deleted in some hemangioblastoma patients and is
amplified in others may suggest that these tumors actually
originate from different cellular lineages. In fact, we found
that spinal tumors were overwhelmingly deleted in the
PTPN11 region: 5 of 7 spinal tumors were deleted whilst 1
was amplified and 1 was chromosomally normal at this
locus. In contrast, cerebellar hemangioblastomas were
generally amplified: 16 out 37 were indeed amplified.
However, 10 cerebellar tumors were deleted and 11 of 37
were normal in this genomic region. Interestingly, differ-
ential overexpression or deletion of PTPN11 has been
shown in other tumors. For example, mutations in
PTPN11 has been reported to be associated with develop-
ment of Juvenile Myelomonocytic Leukemia (JMML) [41],
acute myeloblastic leukemia (AML) [42], and acute
lymphoblastic leukemia (ALL) [43]. Overexpression in
gastric carcinomas has been reported [44]. In contrast,
PTPN11 has a tumor-suppressor function in liver [45] and
cartilage [46]. Accordingly, decreased PTPN11 expression
was detected in a subfraction of human hepatocellular
carcinoma specimens [45]. Thus, in contrast to its com-
mon pro-oncogenic role in hematopoietic and epithelial
cells, PTPN11 may act as a tumor suppressor in cartilage.
Accordingly, we hypothesize that the PTPN11 gene may
Fig. 7 PTPN11 Copy number variation (CNV) values for clinical samples and one normal genomic DNA sample. Genomic DNA copy number
alterations were assessed via ddPCR. The CNV is shown as the number of copies and the Poisson distribution at 95 % confidence interval. The
copy number value of normal diploid sequence has a score of two. Copy number above two means amplification in that region and copy
number below two means deletion in that region
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act in a cell-specific manner: as a tumor suppressor on
one hand in the progenitor cells of spinal hemangioblasto-
mas, whilst it acts as an oncogene in the cells of origin of
cerebellar hemangioblastoma tumors.
Previous analysis of six VHL-related CNS hemangio-
blastomas showed loss of chromosome 3p or the whole
of chromosome 3 to be the most common abnormality,
which is detected in 70 % and loss of 1p11-p31 in 10 %
[47]. More relevant to our findings, published CGH
studies on 10 sporadic cerebellar hemangioblastomas
detected losses of chromosomes 3 (70 %), 6 (50 %), 9
(30 %), and 18q (30 %) and a gain of chromosome 19
(30 %) [48]. We indeed detected losses and gains in
these areas but they were not frequent (15-20 %).
Chromosome 3 losses were more abundant, mostly on
p13 (5 samples FOXP1) and p25 (3 samples showed
PPARG loss and 2 samples showed VHL loss). Interest-
ingly, FOXP1 transcription factor, located on chromo-
some 3(p13), can function as a tumor suppressor gene.
Low expression in glioma [49] and Hodgkin lymphoma
has been shown [50]. Differences in methodology, sam-
ple size and definition of aberration inclusion criteria
may account for some of the apparent inconsistencies
between previous studies and our findings. For example,
previous results were obtained from VHL-related
hemangioblastomas using techniques that identify dele-
tions that are larger than 2 Mb. In the current study we
used modern CGH microarrays which scan the DNA
every 1 kb and thus we were able to identify very subtle
genomic changes. One of the most striking observations
in our study is that many CNVs affected single genes
(Table 3) and revealed candidate genes, which have not
been implicated in hemangioblastomas. This represents
an important outcome of this study compared with pre-
vious investigations using CGH. Some of the new genes
identified here as affected by CNVs in hemangioblas-
toma may serve as targets for future precisely targeted
anti- cancer therapy. For example, antiangiogenic ther-
apy can be given to patients with lesions that are not
resectable.
Conclusions
In this study, we have demonstrated in two different
tumor cohorts and using two different techniques for copy
number alteration detection, SNP and digital PCR, that
Chek2 is deleted and EGFR, PTPN11, Ptch1 amplified in
majority of hemangioblastoma patients. EGFR is the only
gene that has been previously reported as a candidate gene
with hemangioblastoma. Independent of HB tumor loca-
tion PTPN11 may act as tumor suppressor or oncogene
depending on the tumor cell of origin. These findings have
potentially relevant clinical value, as this the first high
resolution for chromosomal alteration in HB. Future re-
search should be dedicated to the prospective validation
of these alterations and further characterization of tumors
that carry the deletions/amplifications, as well as of defin-
ing the role of these genes. This may offer insights into
hemangioblastoma biology, provide DNA-based markers
that can be analyzed by FISH suitable for routine clinical
applications and eventually lead to the development of
effective targeted therapies for HB.
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